Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04543110
Title Radiation and Durvalumab Immunotherapy As Neoadjuvant Treatment for MIBC (RADIANT)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Ottawa Hospital Research Institute
Indications

transitional cell carcinoma

sarcomatoid transitional cell carcinoma

Therapies

Durvalumab

Age Groups: adult | senior
Covered Countries CAN


No variant requirements are available.